| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH COMMUNICATION |
1 From the Department of Clinical and Experimental Medicine (SF, DG, NM, OO, VL, CB, FP, and RC), the Institute of Clinical Chemistry (GF), and the Institute of Cardiology (FB), University of Verona School of Medicine, Verona, Italy.
Background: Low concentrations of pyridoxal-5'-phosphate (PLP), the active metabolite of vitamin B-6, are associated with high C-reactive protein (CRP) concentrations. Both low PLP and elevated inflammatory markers, such as high-sensitivity CRP (hs-CRP) and fibrinogen, are related to higher risk of coronary artery disease (CAD).
Objectives: The objectives were to evaluate the relation between PLP and acute-phase reactants in affecting CAD risk and to estimate the risk of CAD related to low plasma PLP, either alone or in combination with high concentrations of acute-phase reactants and other classic risk factors for CAD.
Design: A case-control study was conducted with 742 participants: 475 with severe multivessel CAD and 267 free from coronary atherosclerosis (CAD-free). We measured plasma PLP, fibrinogen, hs-CRP, and serum lipid concentrations and all major biochemical CAD risk factors, including total homocysteine.
Results: A significant, inverse, graded relation was observed between PLP and both hs-CRP and fibrinogen (P < 0.001). The prevalence of PLP concentrations in the lower half of the population (<50th percentile: 36.3 nmol/L) was significantly higher among CAD patients than among CAD-free subjects (P < 0.001). The odds ratio for CAD risk related to low PLP concentrations after adjustments for the major classic CAD risk factors, including hs-CRP and fibrinogen, was 1.89 (95% CI: 1.18, 3.03; P = 0.008). The CAD risk as a result of low PLP was additive when considered in combination with elevated hs-CRP concentrations or with an increased ratio of LDL to HDL.
Conclusion: Low plasma PLP concentrations are inversely related to major markers of inflammation and independently associated with increased CAD risk.
Key Words: Vitamin B-6 • coronary artery disease • inflammation • C-reactive protein • fibrinogen • homocysteine • LDL:HDL ratio
This article has been cited by other articles:
|
|
 |
|
  J. Dierkes, C. Weikert, K. Klipstein-Grobusch, S. Westphal, C. Luley, M. Mohlig, J. Spranger, and H. Boeing Plasma pyridoxal-5-phosphate and future risk of myocardial infarction in the European Prospective Investigation into Cancer and Nutrition Potsdam cohort Am. J. Clinical Nutrition, July 1, 2007; 86(1): 214 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Melanson Dietary Factors in Reducing Risk of Cardiovascular Diseases American Journal of Lifestyle Medicine, January 1, 2007; 1(1): 24 - 28. [Abstract] [PDF]
|
|
|
|
 |
|
 A. M. Gori, F. Sofi, A. M. Corsi, A. Gazzini, I. Sestini, F. Lauretani, S. Bandinelli, G. F. Gensini, L. Ferrucci, and R. Abbate Predictors of Vitamin B6 and Folate Concentrations in Older Persons: The InCHIANTI Study Clin. Chem., July 1, 2006; 52(7): 1318 - 1324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Rybak, R. B. Jain, and C. M. Pfeiffer Clinical Vitamin B6 Analysis: An Interlaboratory Comparison of Pyridoxal 5'-Phosphate Measurements in Serum Clin. Chem., July 1, 2005; 51(7): 1223 - 1231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dierkes, K. Hoffmann, K. Klipstein-Grobusch, C. Weikert, H. Boeing, B.-C. Zyriax, E. Windler, and J. Kratzsch Low plasma pyridoxal-5'phosphate and cardiovascular disease risk in women: results from the Coronary Risk Factors for Atherosclerosis in Women Study Am. J. Clinical Nutrition, March 1, 2005; 81(3): 725 - 727. [Full Text] [PDF]
|
|
|
|
|
|
S. Friso, D. Girelli, N. Martinelli, O. Olivieri, and R. Corrocher Reply to J Dierkes et al Am. J. Clinical Nutrition, March 1, 2005; 81(3): 727 - 728. [Full Text] [PDF]
|
|
|
|
|
|
R. D Reynolds and J. E Leklem Vitamin B-6 status and coronary artery disease Am. J. Clinical Nutrition, November 1, 2004; 80(5): 1448 - 1449. [Full Text] [PDF]
|
|
|
|
|
|
S. Friso, D. Girelli, and R. Corrocher Reply to RD Reynolds and JE Leklem Am. J. Clinical Nutrition, November 1, 2004; 80(5): 1449 - 1449. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
